Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus

NCT01945021 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01945021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01945021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
January 22, 2020
Enrollment
129 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

crizotinib, non small cell lung cancer, ros1 proto oncogene